TurkmenistanTuberculosis profile
Population  2015 5.4 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.46 (0.42–0.49) 8.5 (7.8–9.2)
Mortality (HIV+TB only) 0 (–) 0 (–)
Incidence  (includes HIV+TB) 3.8 (2.9–4.8) 70 (54–88)
Incidence (HIV+TB only)        
Incidence (MDR/RR-TB)** 0.85 (0.67–1) 16 (12–19)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.18 (0.087–0.27) 1.1 (0.59–1.7) 1.3 (0.67–1.9)
Males 0.19 (0.12–0.26) 2.3 (1.7–2.8) 2.5 (1.8–3.1)
Total 0.37 (0.25–0.49) 3.4 (2.9–3.9) 3.8 (2.9–4.8)
TB case notifications, 2015  
Total cases notified 3 309
Total new and relapse 3 028
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status  
          - % pulmonary 50%
          - % bacteriologically confirmed among pulmonary 69%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.12 (0.1–0.16)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 0  
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  360
(310–420)
Estimated % of TB cases with MDR/RR-TB 14% (11–17) 38% (31–46)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: 270, XDR-TB:
Patients started on treatment **** MDR/RR-TB: 270, XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 85% 2 122
Previously treated cases, excluding relapse, registered in 2014 65% 143
HIV-positive TB cases, all types, registered in 2014   0
MDR/RR-TB cases started on second-line treatment in 2013 0% 81
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-07-24 Data: www.who.int/tb/data